{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:00:40Z","timestamp":1793721640426,"version":"4.6.1"},"reference-count":230,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41571-025-01104-z","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:01:34Z","timestamp":1767610894000},"page":"158-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advances in the management of localized bladder cancers"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7823-4857","authenticated-orcid":false,"given":"Marie-Pier","family":"St-Laurent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-2012","authenticated-orcid":false,"given":"Jussi","family":"Nikkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-7068","authenticated-orcid":false,"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"1104_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","volume":"42","author":"A W\u00e9ber","year":"2024","unstructured":"W\u00e9ber, A. et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J. Urol. 42, 237 (2024).","journal-title":"World J. Urol."},{"key":"1104_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.euo.2019.01.015","volume":"3","author":"FA Sloan","year":"2020","unstructured":"Sloan, F. A., Yashkin, A. P., Akushevich, I. & Inman, B. A. The cost to medicare of bladder cancer care. Eur. Urol. Oncol. 3, 515\u2013522 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek, R. S. et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur. Urol. 66, 253\u2013262 (2014).","journal-title":"Eur. Urol."},{"key":"1104_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes, J. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024).","journal-title":"Eur. Urol."},{"key":"1104_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02568-1 (2023).","journal-title":"Nat. Med."},{"key":"1104_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16366","author":"F Ditonno","year":"2024","unstructured":"Ditonno, F. et al. Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int. https:\/\/doi.org\/10.1111\/bju.16366 (2024).","journal-title":"BJU Int."},{"key":"1104_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero, P. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2014 a summary of the 2024 guidelines update. Eur. Urol. 86, 531\u2013549 (2024).","journal-title":"Eur. Urol."},{"key":"1104_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.euo.2024.01.017","volume":"7","author":"JD Subiela","year":"2024","unstructured":"Subiela, J. D. et al. Unlocking the potential of adequate Bacillus Calmette\u2013Gu\u00e9rin immunotherapy in very-high-risk non-muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics. Eur. Urol. Oncol. 7, 1367\u20131375 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein, J. M. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J. Urol. 211, 533\u2013538 (2024).","journal-title":"J. Urol."},{"key":"1104_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J. Urol. 196, 1021\u20131029 (2016).","journal-title":"J. Urol."},{"key":"1104_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/JU.0000000000002678","volume":"208","author":"KK Bree","year":"2022","unstructured":"Bree, K. K. et al. All high-grade Ta tumors should be classified as high risk: Bacillus Calmette\u2013Gu\u00e9rin response in high-grade Ta tumors. J. Urol. 208, 284\u2013291 (2022).","journal-title":"J. Urol."},{"key":"1104_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75\u201394 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.01.001","author":"D Annapureddy","year":"2025","unstructured":"Annapureddy, D. et al. Impact of tumor stage on oncologic outcomes of high-grade Bacillus Calmette\u2013Gu\u00e9rin unresponsive non-muscle-invasive bladder cancer undergoing bladder-sparing therapies. Eur. Urol. Focus https:\/\/doi.org\/10.1016\/j.euf.2025.01.001 (2025).","journal-title":"Eur. Urol. Focus"},{"key":"1104_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.euo.2023.01.004","volume":"6","author":"IJ Beijert","year":"2023","unstructured":"Beijert, I. J., Hentschel, A. E., Br\u00fcndl, J., Comp\u00e9rat, E. M. & Plass, K. Prognosis of primary papillary Ta grade 3 bladder cancer in the non-muscle-invasive spectrum. Eur. Urol. Oncol. 6, 214\u2013221 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.02.003","author":"M-P St-Laurent","year":"2023","unstructured":"St-Laurent, M.-P., Suderman, J. & Black, P. C. Where to draw the line: stratifying risk for high-grade Ta bladder cancer. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2023.02.003 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.euo.2022.07.003","volume":"5","author":"F Soria","year":"2022","unstructured":"Soria, F. & Gontero, P. Intermediate-risk non-muscle-invasive bladder cancer: time to tidy up the mess? Eur. Urol. Oncol. 5, 517\u2013518 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","volume":"5","author":"WS Tan","year":"2022","unstructured":"Tan, W. S. et al. Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group. Eur. Urol. Oncol. 5, 505\u2013516 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","volume":"20","author":"M Maas","year":"2023","unstructured":"Maas, M., Todenh\u00f6fer, T. & Black, P. C. Urine biomarkers in bladder cancer \u2014 current status and future perspectives. Nat. Rev. Urol. 20, 597\u2013614 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/iju.15338","volume":"31","author":"E Tomiyama","year":"2024","unstructured":"Tomiyama, E., Fujita, K., Hashimoto, M., Uemura, H. & Nonomura, N. Urinary markers for bladder cancer diagnosis: a review of current status and future challenges. Int. J. Urol. 31, 208\u2013219 (2024).","journal-title":"Int. J. Urol."},{"key":"1104_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euo.2018.04.010","volume":"1","author":"Y Lotan","year":"2018","unstructured":"Lotan, Y. et al. Optimal trial design for studying urinary markers in bladder cancer: a collaborative review. Eur. Urol. Oncol. 1, 223\u2013230 (2018).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.euros.2024.02.018","volume":"63","author":"FR Schroeck","year":"2024","unstructured":"Schroeck, F. R. et al. Clinical trial protocol for \u2018replace cysto\u2019: replacing invasive cystoscopy with urine testing for non-muscle-invasive bladder cancer surveillance \u2014 a multicenter, randomized, phase 2 healthcare delivery trial comparing quality of life during cancer surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy. Eur. Urol. Open Sci. 63, 19\u201330 (2024).","journal-title":"Eur. Urol. Open Sci."},{"key":"1104_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","volume":"88","author":"DT Karmark","year":"2025","unstructured":"Karmark, D. T. et al. The DaBlaCa-15 trial: the urinary biomarker test Xpert Bladder Cancer Monitor guiding cystoscopy in high-grade non-muscle-invasive bladder cancer: results from a randomized controlled trial. Eur. Urol. 88, 23\u201330 (2025).","journal-title":"Eur. Urol."},{"key":"1104_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","volume":"85","author":"T Strandgaard","year":"2024","unstructured":"Strandgaard, T. et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur. Urol. 85, 82\u201392 (2024).","journal-title":"Eur. Urol."},{"key":"1104_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1200\/JCO.2024.42.4_suppl.529","volume":"42","author":"M-P St-Laurent","year":"2024","unstructured":"St-Laurent, M.-P. et al. Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605. J. Clin. Oncol. 42, 529 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.016","author":"VM Narayan","year":"2024","unstructured":"Narayan, V. M. et al. Minimal residual disease detection with urine-derived DNA is prognostic for recurrence-free survival in Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer treated with nadofaragene firadenovec. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.09.016 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"Catto, J. W. F. et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann. Oncol. 35, 98\u2013106 (2024).","journal-title":"Ann. Oncol."},{"key":"1104_CR27","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","volume":"319","author":"EM Messing","year":"2018","unstructured":"Messing, E. M. et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. Jama 319, 1880\u20131888 (2018).","journal-title":"Jama"},{"key":"1104_CR28","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester, R. J., van der, M. A. & Lamm, D. L. Intravesical Bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964\u20131970 (2002).","journal-title":"J. Urol."},{"key":"1104_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens, J. et al. Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette\u2013Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 63, 462\u2013472 (2013).","journal-title":"Eur. Urol."},{"key":"1104_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","volume":"4","author":"WB Tabayoyong","year":"2018","unstructured":"Tabayoyong, W. B. et al. Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer. Eur. Urol. Focus 4, 512\u2013521 (2018).","journal-title":"Eur. Urol. Focus"},{"key":"1104_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.10939.x","volume":"110","author":"P Turker","year":"2012","unstructured":"Turker, P. et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int. 110, 804\u2013811 (2012).","journal-title":"BJU Int."},{"key":"1104_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41585-024-00904-9","volume":"22","author":"E Shkolyar","year":"2025","unstructured":"Shkolyar, E. et al. Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence. Nat. Rev. Urol. 22, 46\u201354 (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR33","first-page":"CD014887","volume":"4","author":"LY Lai","year":"2022","unstructured":"Lai, L. Y. et al. Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database Syst. Rev. 4, CD014887 (2022).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1104_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/sj.bjc.6690338","volume":"80","author":"N Lange","year":"1999","unstructured":"Lange, N. et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br. J. Cancer 80, 185\u2013193 (1999).","journal-title":"Br. J. Cancer"},{"key":"1104_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1117\/1.1695563","volume":"9","author":"K Gono","year":"2004","unstructured":"Gono, K. et al. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J. Biomed. Opt. 9, 568\u2013577 (2004).","journal-title":"J. Biomed. Opt."},{"key":"1104_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/jnci\/djab179","volume":"114","author":"S Wu","year":"2022","unstructured":"Wu, S. et al. An artificial intelligence system for the detection of bladder cancer via cystoscopy: a multicenter diagnostic study. J. Natl Cancer Inst. 114, 220\u2013227 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"1104_CR37","doi-asserted-by":"publisher","DOI":"10.1089\/end.2023.0056","author":"TC Chang","year":"2023","unstructured":"Chang, T. C. et al. Real-time detection of bladder cancer using augmented cystoscopy with deep learning: a pilot study. J. Endourol. https:\/\/doi.org\/10.1089\/end.2023.0056 (2023).","journal-title":"J. Endourol."},{"key":"1104_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074142","volume":"8","author":"H Yuan","year":"2013","unstructured":"Yuan, H. et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS ONE 8, e74142 (2013).","journal-title":"PLoS ONE"},{"key":"1104_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euros.2021.06.011","volume":"31","author":"R Veeratterapillay","year":"2021","unstructured":"Veeratterapillay, R. et al. Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer. Eur. Urol. Open Sci. 31, 17\u201327 (2021).","journal-title":"Eur. Urol. Open Sci."},{"key":"1104_CR40","doi-asserted-by":"publisher","first-page":"EVIDoa2200092","DOI":"10.1056\/EVIDoa2200092","volume":"1","author":"R Heer","year":"2022","unstructured":"Heer, R. et al. A randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer. NEJM Evid. 1, EVIDoa2200092 (2022).","journal-title":"NEJM Evid."},{"key":"1104_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.eururo.2022.12.018","volume":"83","author":"MP St-Laurent","year":"2023","unstructured":"St-Laurent, M. P., Suderman, J. & Black, P. C. Re: a randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer. Eur. Urol. 83, 298\u2013299 (2023).","journal-title":"Eur. Urol."},{"key":"1104_CR42","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1007\/s00345-023-04547-0","volume":"41","author":"JY Teoh","year":"2023","unstructured":"Teoh, J. Y. et al. En bloc resection of bladder tumour: the rebirth of past through reminiscence. World J. Urol. 41, 2599\u20132606 (2023).","journal-title":"World J. Urol."},{"key":"1104_CR43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","volume":"19","author":"JY Teoh","year":"2022","unstructured":"Teoh, J. Y. et al. Recurrence mechanisms of non-muscle-invasive bladder cancer \u2014 a clinical perspective. Nat. Rev. Urol. 19, 280\u2013294 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.10.004","author":"G Basile","year":"2024","unstructured":"Basile, G. et al. En bloc versus conventional transurethral resection of bladder tumors: a systematic review and meta-analysis of oncological, histopathological, and surgical outcomes. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.10.004 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.eururo.2024.04.015","volume":"86","author":"J Yuen-Chun Teoh","year":"2024","unstructured":"Yuen-Chun Teoh, J. et al. Transurethral en bloc resection versus standard resection of bladder tumour: a randomised, multicentre, phase 3 trial. Eur. Urol. 86, 103\u2013111 (2024).","journal-title":"Eur. Urol."},{"key":"1104_CR46","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.euo.2023.07.010","volume":"6","author":"D D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea, D. et al. En bloc versus conventional resection of primary bladder tumor (eBLOC): a prospective, multicenter, open-label, phase 3 randomized controlled trial. Eur. Urol. Oncol. 6, 508\u2013515 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41585-018-0092-z","volume":"15","author":"WS Tan","year":"2018","unstructured":"Tan, W. S. & Kelly, J. D. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat. Rev. Urol. 15, 667\u2013685 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41585-019-0220-4","volume":"16","author":"GA Joice","year":"2019","unstructured":"Joice, G. A., Bivalacqua, T. J. & Kates, M. Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. Nat. Rev. Urol. 16, 599\u2013612 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","volume":"83","author":"WS Tan","year":"2023","unstructured":"Tan, W. S. et al. Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial. Eur. Urol. 83, 497\u2013504 (2023).","journal-title":"Eur. Urol."},{"key":"1104_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","volume":"6","author":"JC Angulo","year":"2023","unstructured":"Angulo, J. C. et al. Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial. Eur. Urol. Oncol. 6, 58\u201366 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","volume":"40","author":"F Guerrero-Ramos","year":"2022","unstructured":"Guerrero-Ramos, F. et al. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J. Urol. 40, 999\u20131004 (2022).","journal-title":"World J. Urol."},{"key":"1104_CR52","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","volume":"170","author":"MS Soloway","year":"2003","unstructured":"Soloway, M. S., Bruck, D. S. & Kim, S. S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J. Urol. 170, 438\u2013441 (2003).","journal-title":"J. Urol."},{"key":"1104_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.euo.2024.08.001","volume":"8","author":"R Contieri","year":"2025","unstructured":"Contieri, R. et al. Deintensification of treatment for low-grade bladder tumors: a collaborative review by the International Bladder Cancer Group (IBCG). Eur. Urol. Oncol. 8, 179\u2013189 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.eururo.2022.08.012","volume":"83","author":"GL Pedersen","year":"2023","unstructured":"Pedersen, G. L., Erikson, M. S., Mogensen, K., Rosth\u00f8j, S. & Hermann, G. G. Outpatient photodynamic diagnosis-guided laser destruction of bladder tumors is as good as conventional inpatient photodynamic diagnosis-guided transurethral tumor resection in patients with recurrent intermediate-risk low-grade Ta bladder tumors. A prospective randomized noninferiority clinical trial. Eur. Urol. 83, 125\u2013130 (2023).","journal-title":"Eur. Urol."},{"key":"1104_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","volume":"5","author":"R Contieri","year":"2022","unstructured":"Contieri, R. et al. Long-term follow-up and factors associated with active surveillance failure for patients with non-muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance (BIAS) experience. Eur. Urol. Oncol. 5, 251\u2013255 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","volume":"9","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa, T. et al. A systematic review and meta-analysis of chemoablation for non-muscle-invasive bladder cancer. Eur. Urol. Focus 9, 463\u2013479 (2023).","journal-title":"Eur. Urol. Focus"},{"key":"1104_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JU.0000000000004296","volume":"213","author":"SM Prasad","year":"2025","unstructured":"Prasad, S. M. et al. Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION). J. Urol. 213, 205\u2013216 (2025).","journal-title":"J. Urol."},{"key":"1104_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JU.0000000000003645","volume":"210","author":"SM Prasad","year":"2023","unstructured":"Prasad, S. M. et al. Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102\u2009\u00b1\u2009transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS). J. Urol. 210, 619\u2013629 (2023).","journal-title":"J. Urol."},{"key":"1104_CR59","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1200\/JCO.22.00470","volume":"41","author":"MS Lindgren","year":"2023","unstructured":"Lindgren, M. S. et al. DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial. J. Clin. Oncol. 41, 206\u2013211 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR60","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.euo.2018.08.032","volume":"2","author":"M Racioppi","year":"2019","unstructured":"Racioppi, M. et al. Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non-muscle-invasive bladder cancer. Eur. Urol. Oncol. 2, 576\u2013583 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR61","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/bju.15038","volume":"125","author":"AH Mostafid","year":"2020","unstructured":"Mostafid, A. H. et al. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int. 125, 817\u2013826 (2020).","journal-title":"BJU Int."},{"key":"1104_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette\u2013Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247\u2013256 (2009).","journal-title":"Eur. Urol."},{"key":"1104_CR63","first-page":"123","volume":"20","author":"A Ansari Djafari","year":"2023","unstructured":"Ansari Djafari, A. et al. Intravesical gemcitabine versus intravesical Bacillus Calmette\u2013Guerin for the treatment of intermediate-risk non-muscle invasive bladder cancer: a randomized controlled trial. Urol. J. 20, 123\u2013128 (2023).","journal-title":"Urol. J."},{"key":"1104_CR64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle, A., Jocham, D. & Bock, P. R. Intravesical Bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169, 90\u201395 (2003).","journal-title":"J. Urol."},{"key":"1104_CR65","first-page":"E424","volume":"15","author":"B Bhindi","year":"2021","unstructured":"Bhindi, B. et al. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer \u2014 full-text. Can. Urol. Assoc. J. 15, E424\u2013E460 (2021).","journal-title":"Can. Urol. Assoc. J."},{"key":"1104_CR66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849","volume":"6","author":"IM McElree","year":"2023","unstructured":"McElree, I. M., Steinberg, R. L., Mott, S. L., O\u2019Donnell, M. A. & Packiam, V. T. Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette\u2013Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer. JAMA Netw. Open 6, e230849 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1104_CR67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/JU.0000000000003977","volume":"212","author":"SH Patel","year":"2024","unstructured":"Patel, S. H. et al. A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette\u2013Gu\u00e9rin-naive nonmuscle-invasive urothelial carcinoma of the bladder. J. Urol. 212, 95\u2013103 (2024).","journal-title":"J. Urol."},{"key":"1104_CR68","unstructured":"FDA (ed. U.S. Department of Health and Human Services Food and Drug Administration). https:\/\/www.fda.gov\/media\/101468\/download (2024)."},{"key":"1104_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03738-z","author":"ND Shore","year":"2025","unstructured":"Shore, N. D. et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03738-z (2025).","journal-title":"Nat. Med."},{"key":"1104_CR70","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.01","volume":"213","author":"ND Shore","year":"2025","unstructured":"Shore, N. D. et al. Sasanlimab in combination with Bacillus Calmette\u2013Gu\u00e9rin improves event-free survival versus Bacillus Calmette\u2013Gu\u00e9rin as standard of care in high-risk non-muscle-invasive bladder cancer: phase 3 crest study results. J. Urol. 213, e1 (2025).","journal-title":"J. Urol."},{"key":"1104_CR71","doi-asserted-by":"publisher","unstructured":"De Santis, M. et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(25)01897-5 (2025).","DOI":"10.1016\/S0140-6736(25)01897-5"},{"key":"1104_CR72","unstructured":"Bowden, M. Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/imfinzi-improved-dfs-in-early-bladder-cancer.html (2025)."},{"key":"1104_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.017","author":"M Roupret","year":"2025","unstructured":"Roupret, M. et al. ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC). Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017 (2025).","journal-title":"Ann. Oncol."},{"key":"1104_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","volume":"82","author":"M Roumigui\u00e9","year":"2022","unstructured":"Roumigui\u00e9, M. et al. International Bladder Cancer Group consensus statement on clinical trial design for patients with Bacillus Calmette\u2013Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer. Eur. Urol. 82, 34\u201346 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR75","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig, T. W. et al. NCCN guidelines\u00ae insights: bladder cancer, version 3.2024. J. Natl Compr. Canc. Netw. 22, 216\u2013225 (2024).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"1104_CR76","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr, H. W. & Sogani, P. C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 166, 1296\u20131299 (2001).","journal-title":"J. Urol."},{"key":"1104_CR77","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.juro.2006.03.038","volume":"176","author":"RE Hautmann","year":"2006","unstructured":"Hautmann, R. E., Gschwend, J. E., de Petriconi, R. C., Kron, M. & Volkmer, B. G. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J. Urol. 176, 486\u2013492 (2006).","journal-title":"J. Urol."},{"key":"1104_CR78","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1590\/s1677-5538.ibju.2022.0405","volume":"49","author":"S Sobhani","year":"2023","unstructured":"Sobhani, S. et al. Perioperative mortality for radical cystectomy in the modern era: experience from a tertiary referral center. Int. Braz. J. Urol. 49, 351\u2013358 (2023).","journal-title":"Int. Braz. J. Urol."},{"key":"1104_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043266","volume":"11","author":"SL Maibom","year":"2021","unstructured":"Maibom, S. L. et al. Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open 11, e043266 (2021).","journal-title":"BMJ Open"},{"key":"1104_CR80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bju.14636","volume":"124","author":"M Mossanen","year":"2019","unstructured":"Mossanen, M. et al. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int. 124, 40\u201346 (2019).","journal-title":"BJU Int."},{"key":"1104_CR81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euros.2023.04.013","volume":"53","author":"WS Tan","year":"2023","unstructured":"Tan, W. S. et al. Bladder-sparing treatment in patients with Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: an analysis of long-term survival outcomes. Eur. Urol. Open Sci. 53, 16\u201322 (2023).","journal-title":"Eur. Urol. Open Sci."},{"key":"1104_CR82","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bju.16509","volume":"135","author":"JI Taylor","year":"2025","unstructured":"Taylor, J. I. et al. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 135, 260\u2013268 (2025).","journal-title":"BJU Int."},{"key":"1104_CR83","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1097\/01.JU.0001111604.90306.91.05","volume":"213","author":"JL Gore","year":"2025","unstructured":"Gore, J. L. et al. Radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: results from the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study. J. Urol. 213, e3\u2013e4 (2025).","journal-title":"J. Urol."},{"key":"1104_CR84","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CP Dinney","year":"2013","unstructured":"Dinney, C. P., Greenberg, R. E. & Steinberg, G. D. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after Bacillus Calmette\u2013Gu\u00e9rin. Urol. Oncol. 31, 1635\u20131642 (2013).","journal-title":"Urol. Oncol."},{"key":"1104_CR85","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg, G. et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette\u2013Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 163, 761\u2013767 (2000).","journal-title":"J. Urol."},{"key":"1104_CR86","unstructured":"NCC Network. NCCN Clinical Practice Guidelines in Oncology (Bladder Cancer). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (2025)."},{"key":"1104_CR87","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919\u2013930 (2021).","journal-title":"Lancet Oncol."},{"key":"1104_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.004","author":"PC Black","year":"2023","unstructured":"Black, P. C. et al. Phase 2 trial of atezolizumab in Bacillus Calmette\u2013Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.004 (2023).","journal-title":"Eur. Urol."},{"key":"1104_CR89","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","volume":"29","author":"R Li","year":"2023","unstructured":"Li, R. et al. A phase II study of durvalumab for Bacillus Calmette\u2013Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder. Clin. Cancer Res. 29, 3875\u20133881 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR90","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi, A. et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 25, 720\u2013730 (2024).","journal-title":"Lancet Oncol."},{"key":"1104_CR91","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian, S. A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22, 107\u2013117 (2021).","journal-title":"Lancet Oncol."},{"key":"1104_CR92","unstructured":"FDA. in 761336Orig1s000 (ed. Center for Drug Evaluation and Research). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761336Orig1s000MultidisciplineR.pdf (2024)."},{"key":"1104_CR93","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","volume":"180","author":"S Dubois","year":"2008","unstructured":"Dubois, S., Patel, H. J., Zhang, M., Waldmann, T. A. & M\u00fcller, J. R. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action. J. Immunol. 180, 2099\u20132106 (2008).","journal-title":"J. Immunol."},{"key":"1104_CR94","doi-asserted-by":"publisher","first-page":"9166","DOI":"10.1073\/pnas.0600240103","volume":"103","author":"MP Rubinstein","year":"2006","unstructured":"Rubinstein, M. P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl Acad. Sci. USA 103, 9166\u20139171 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR95","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie, K. et al. IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid. 2, EVIDoa2200167 (2023).","journal-title":"NEJM Evid."},{"key":"1104_CR96","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor \u2014 armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12, 305\u2013313 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR97","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.02","volume":"213","author":"MD Tyson","year":"2025","unstructured":"Tyson, M. D. et al. Final results: BOND-003 cohort C-phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. J. Urol. 213, e1 (2025).","journal-title":"J. Urol."},{"key":"1104_CR98","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","volume":"30","author":"R Li","year":"2024","unstructured":"Li, R. et al. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat. Med. 30, 2216\u20132223 (2024).","journal-title":"Nat. Med."},{"key":"1104_CR99","doi-asserted-by":"publisher","unstructured":"Daneshmand, S. et al. TAR-200 for Bacillus Calmette\u2013Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/jco-25-01651 (2025).","DOI":"10.1200\/jco-25-01651"},{"key":"1104_CR100","doi-asserted-by":"publisher","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","volume":"40","author":"RL Steinberg","year":"2022","unstructured":"Steinberg, R. L. et al. Intravesical sequential gemcitabine and docetaxel versus Bacillus Calmette\u2013Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol. Oncol. 40, 9.e1\u20139.e7 (2022).","journal-title":"Urol. Oncol."},{"key":"1104_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16645","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti, P. et al. Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int. https:\/\/doi.org\/10.1111\/bju.16645 (2025).","journal-title":"BJU Int."},{"key":"1104_CR102","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","volume":"8","author":"J Taylor","year":"2025","unstructured":"Taylor, J. et al. Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with Bacillus Calmette\u2013Gu\u00e9rin in patients with Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer. Eur. Urol. Oncol. 8, 469\u2013476 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR103","doi-asserted-by":"publisher","first-page":"TPS901","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS901","volume":"43","author":"T Bivalacqua","year":"2025","unstructured":"Bivalacqua, T., Daneshmand, S., Shore, N. D., Joshi, S. & Dinney, C. P. N. CORE-008: a phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer. J. Clin. Oncol. 43, TPS901 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR104","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.urolonc.2024.12.137","volume":"43","author":"S Porten","year":"2025","unstructured":"Porten, S. et al. SunRISe-5: a phase 3, randomized, open-label study of TAR-200 compared with intravesical chemotherapy after Bacillus Calmette\u2013Gu\u00e9rin in recurrent high-risk non-muscle-invasive bladder cancer. Urol. Oncol. Semin. Original Investig. 43, 54\u201355 (2025).","journal-title":"Urol. Oncol. Semin. Original Investig."},{"key":"1104_CR105","doi-asserted-by":"publisher","first-page":"PR005","DOI":"10.1158\/1557-3265.BLADDER24-PR005","volume":"30","author":"SM Alam","year":"2024","unstructured":"Alam, S. M. et al. Abstract PR005: final results from a phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette\u2013Gu\u00e9rin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer. Clin. Cancer Res. 30, PR005 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR106","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco, V. et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur. Urol. 74, 294\u2013306 (2018).","journal-title":"Eur. Urol."},{"key":"1104_CR107","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/2090598X.2020.1733818","volume":"18","author":"R Carando","year":"2020","unstructured":"Carando, R. et al. The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): a systematic review. Arab. J. Urol. 18, 67\u201371 (2020).","journal-title":"Arab. J. Urol."},{"key":"1104_CR108","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.acuro.2023.04.001","volume":"47","author":"O Kazan","year":"2023","unstructured":"Kazan, O. et al. Diagnostic validity of the vesical imaging-reporting and data system (VI-RADS): a real-world study. Actas Urol. Esp. 47, 638\u2013644 (2023).","journal-title":"Actas Urol. Esp."},{"key":"1104_CR109","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO-25-00779","volume":"43","author":"RT Bryan","year":"2025","unstructured":"Bryan, R. T. et al. Randomized comparison of magnetic resonance imaging versus transurethral resection for staging new bladder cancers: results from the prospective BladderPath trial. J. Clin. Oncol. 43, 1417\u20131428 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR110","doi-asserted-by":"publisher","unstructured":"James, N. D. et al. Randomized comparison of upfront magnetic resonance imaging versus transurethral resection for staging new bladder cancers: Final survival analysis from the BladderPath trial. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.130 (2025).","DOI":"10.1016\/j.annonc.2025.09.130"},{"key":"1104_CR111","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00261-021-03365-5","volume":"47","author":"M Pecoraro","year":"2022","unstructured":"Pecoraro, M. et al. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom. Radiol. 47, 763\u2013770 (2022).","journal-title":"Abdom. Radiol."},{"key":"1104_CR112","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16191","author":"A Necchi","year":"2023","unstructured":"Necchi, A. et al. VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. BJU Int. https:\/\/doi.org\/10.1111\/bju.16191 (2023).","journal-title":"BJU Int."},{"key":"1104_CR113","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000351964","volume":"92","author":"N Wang","year":"2014","unstructured":"Wang, N., Jiang, P. & Lu, Y. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for detecting bladder lesions? A meta-analysis of the literature. Urol. Int. 92, 143\u2013149 (2014).","journal-title":"Urol. Int."},{"key":"1104_CR114","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1053\/j.semnuclmed.2021.12.004","volume":"52","author":"K Bouchelouche","year":"2022","unstructured":"Bouchelouche, K. PET\/CT in bladder cancer: an update. Semin. Nucl. Med. 52, 475\u2013485 (2022).","journal-title":"Semin. Nucl. Med."},{"key":"1104_CR115","doi-asserted-by":"publisher","first-page":"109657","DOI":"10.1016\/j.isci.2024.109657","volume":"27","author":"T Li","year":"2024","unstructured":"Li, T. et al. Performance of (18)F-FDG PET\/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer. iScience 27, 109657 (2024).","journal-title":"iScience"},{"key":"1104_CR116","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2024.42.4_suppl.527","volume":"42","author":"A Cigliola","year":"2024","unstructured":"Cigliola, A. et al. Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials. J. Clin. Oncol. 42, 527 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR117","first-page":"241941","volume":"65","author":"C Bezzi","year":"2024","unstructured":"Bezzi, C. et al. Staging and neoadjuvant response evaluation in patients with muscle-invasive bladder cancer (MIBC) using [18F]F-FDG PET\/MRI. J. Nucl. Med. 65, 241941 (2024).","journal-title":"J. Nucl. Med."},{"key":"1104_CR118","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/jmri.26327","volume":"49","author":"X Xu","year":"2019","unstructured":"Xu, X. et al. Quantitative identification of nonmuscle-invasive and muscle-invasive bladder carcinomas: a multiparametric MRI radiomics analysis. J. Magn. Reson. Imaging 49, 1489\u20131498 (2019).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1104_CR119","doi-asserted-by":"publisher","unstructured":"He, K. et al. Progress of multiparameter magnetic resonance imaging in bladder cancer: a comprehensive literature review. Diagnostics (Basel) https:\/\/doi.org\/10.3390\/diagnostics14040442 (2024).","DOI":"10.3390\/diagnostics14040442"},{"key":"1104_CR120","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13244-024-01884-5","volume":"16","author":"Y Arita","year":"2025","unstructured":"Arita, Y. et al. Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer. Insights Imaging 16, 7 (2025).","journal-title":"Insights Imaging"},{"key":"1104_CR121","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.eururo.2009.10.024","volume":"57","author":"J Nix","year":"2010","unstructured":"Nix, J. et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur. Urol. 57, 196\u2013201 (2010).","journal-title":"Eur. Urol."},{"key":"1104_CR122","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","volume":"391","author":"DJ Parekh","year":"2018","unstructured":"Parekh, D. J. et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 391, 2525\u20132536 (2018).","journal-title":"Lancet"},{"key":"1104_CR123","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.eururo.2014.11.043","volume":"67","author":"BH Bochner","year":"2015","unstructured":"Bochner, B. H. et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur. Urol. 67, 1042\u20131050 (2015).","journal-title":"Eur. Urol."},{"key":"1104_CR124","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.eururo.2015.07.038","volume":"69","author":"MS Khan","year":"2016","unstructured":"Khan, M. S. et al. A single-centre early phase randomised Controlled Three-Arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur. Urol. 69, 613\u2013621 (2016).","journal-title":"Eur. Urol."},{"key":"1104_CR125","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1001\/jama.2022.7393","volume":"327","author":"JWF Catto","year":"2022","unstructured":"Catto, J. W. F. et al. Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial. JAMA 327, 2092\u20132103 (2022).","journal-title":"JAMA"},{"key":"1104_CR126","doi-asserted-by":"publisher","unstructured":"Rai, B. P. et al. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD011903.pub2 (2019).","DOI":"10.1002\/14651858.CD011903.pub2"},{"key":"1104_CR127","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2023.04.004","volume":"84","author":"P Khetrapal","year":"2023","unstructured":"Khetrapal, P. et al. Robot-assisted radical cystectomy versus open radical cystectomy: a systematic review and meta-analysis of perioperative, oncological, and quality of life outcomes using randomized controlled trials. Eur. Urol. 84, 393\u2013405 (2023).","journal-title":"Eur. Urol."},{"key":"1104_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-019-1759-5","volume":"17","author":"Y-C Wang","year":"2019","unstructured":"Wang, Y.-C. et al. Extended versus non-extended lymphadenectomy during radical cystectomy for patients with bladder cancer: a meta-analysis of the effect on long-term and short-term outcomes. World J. Surg. Oncol. 17, 225 (2019).","journal-title":"World J. Surg. Oncol."},{"key":"1104_CR129","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A. G. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur. Urol. 87, 582\u2013600 (2025).","journal-title":"Eur. Urol."},{"key":"1104_CR130","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","volume":"391","author":"SP Lerner","year":"2024","unstructured":"Lerner, S. P. et al. Standard or extended lymphadenectomy for muscle-invasive bladder cancer. N. Engl. J. Med. 391, 1206\u20131216 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR131","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","volume":"75","author":"JE Gschwend","year":"2019","unstructured":"Gschwend, J. E. et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur. Urol. 75, 604\u2013611 (2019).","journal-title":"Eur. Urol."},{"key":"1104_CR132","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00345-025-05549-w","volume":"43","author":"A \u015alusarczyk","year":"2025","unstructured":"\u015alusarczyk, A. et al. Comparison of extended and standard lymph node dissection in radical cystectomy for urothelial bladder cancer: a systematic review and meta-analysis. World J. Urol. 43, 181 (2025).","journal-title":"World J. Urol."},{"key":"1104_CR133","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR134","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths, G., Hall, R., Sylvester, R., Raghavan, D. & Parmar, M. K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171\u20132177 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR135","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"CL Vale","year":"2005","unstructured":"Vale, C. L. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202 (2005).","journal-title":"Eur. Urol."},{"key":"1104_CR136","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase, H. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068\u20133077 (2000).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR137","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister, C. et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 25, 255\u2013264 (2024).","journal-title":"Lancet Oncol."},{"key":"1104_CR138","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR139","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden, M. S. et al. Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma. N. Engl. J. Med. 389, 1778\u20131789 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR140","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2217\/fon-2021-0273","volume":"17","author":"MD Galsky","year":"2021","unstructured":"Galsky, M. D. et al. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303. Future Oncol. 17, 3137\u20133150 (2021).","journal-title":"Future Oncol."},{"key":"1104_CR141","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.2217\/fon-2019-0611","volume":"16","author":"G Sonpavde","year":"2020","unstructured":"Sonpavde, G. et al. ENERGIZE: a phase III study of neoadjuvant chemotherapy alone or with nivolumab with\/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncol. 16, 4359\u20134368 (2020).","journal-title":"Future Oncol."},{"key":"1104_CR142","doi-asserted-by":"publisher","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2408154 (2024).","DOI":"10.1056\/NEJMoa2408154"},{"key":"1104_CR143","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","volume":"38","author":"S Gupta","year":"2020","unstructured":"Gupta, S. et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J. Clin. Oncol. 38, 439 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR144","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4143\/crt.2022.343","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim, H. et al. Neoadjuvant nivolumab plus gemcitabine\/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder. Cancer Res. Treat. 55, 636\u2013642 (2023).","journal-title":"Cancer Res. Treat."},{"key":"1104_CR145","doi-asserted-by":"publisher","unstructured":"Vulsteke, C. et al. Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.124 (2025).","DOI":"10.1016\/j.annonc.2025.09.124"},{"key":"1104_CR146","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James, N. D. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med. 366, 1477\u20131488 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR147","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","volume":"82","author":"E Hall","year":"2022","unstructured":"Hall, E. et al. Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial. Eur. Urol. 82, 273\u2013279 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR148","doi-asserted-by":"publisher","first-page":"272.e271","DOI":"10.1016\/j.urolonc.2021.12.015","volume":"40","author":"K Softness","year":"2022","unstructured":"Softness, K. et al. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol. Oncol. 40, 272.e271\u2013272.e279 (2022).","journal-title":"Urol. Oncol."},{"key":"1104_CR149","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta, A. R. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 24, 669\u2013681 (2023).","journal-title":"Lancet Oncol."},{"key":"1104_CR150","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone, N. J. et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital Experience. Eur. Urol. 71, 952\u2013960 (2017).","journal-title":"Eur. Urol."},{"key":"1104_CR151","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","volume":"200","author":"P Mazza","year":"2018","unstructured":"Mazza, P. et al. Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study. J. Urol. 200, 1005\u20131013 (2018).","journal-title":"J. Urol."},{"key":"1104_CR152","doi-asserted-by":"publisher","unstructured":"Geynisman, D. M. et al. Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/jco-24-01214 (2024).","DOI":"10.1200\/jco-24-01214"},{"key":"1104_CR153","doi-asserted-by":"publisher","unstructured":"Culine, S. et al. Refining the characterization and outcome of pathological complete responders after neoadjuvant chemotherapy for muscle-invasive bladder cancer: lessons from the randomized phase III VESPER (GETUG-AFU V05) trial. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15061742 (2023).","DOI":"10.3390\/cancers15061742"},{"key":"1104_CR154","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","volume":"43","author":"P Ghatalia","year":"2025","unstructured":"Ghatalia, P. et al. A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2). J. Clin. Oncol. 43, 815 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR155","doi-asserted-by":"publisher","first-page":"117955492412572","DOI":"10.1177\/11795549241257238","volume":"18","author":"S Balli","year":"2024","unstructured":"Balli, S., Bolek, H. & \u00dcr\u00fcn, Y. Emerging strategies in adjuvant immunotherapy: a comparative review of bladder cancer and renal cell carcinoma treatments. Clin. Med. Insights Oncol. 18, 11795549241257238 (2024).","journal-title":"Clin. Med. Insights Oncol."},{"key":"1104_CR156","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group.","year":"2022","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur. Urol. 81, 50\u201361 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR157","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow, J. J. et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur. Urol. 66, 42\u201354 (2014).","journal-title":"Eur. Urol."},{"key":"1104_CR158","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2024","unstructured":"Galsky, M. D. et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J. Clin. Oncol. 43, 15\u201321 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR159","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"B Apolo Andrea","year":"2025","unstructured":"Apolo Andrea, B. et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 392, 45\u201355 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR160","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt, J. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22, 525\u2013537 (2021).","journal-title":"Lancet Oncol."},{"key":"1104_CR161","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-1860","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog, S. V. et al. Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1860 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.002","author":"R Ben-David","year":"2024","unstructured":"Ben-David, R. et al. Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.03.002 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR163","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR164","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","volume":"29","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat. Med. 29, 588\u2013592 (2023).","journal-title":"Nat. Med."},{"key":"1104_CR165","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"1104_CR166","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"1104_CR167","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. Eur. Urol. 85, 114\u2013122 (2024).","journal-title":"Eur. Urol."},{"key":"1104_CR168","doi-asserted-by":"publisher","unstructured":"Galsky, M. D. et al. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.139 (2025).","DOI":"10.1016\/j.annonc.2025.09.139"},{"key":"1104_CR169","doi-asserted-by":"publisher","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","volume":"35","author":"J Bjerggaard Jensen","year":"2024","unstructured":"Bjerggaard Jensen, J. et al. 1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial. Ann. Oncol. 35, S1133 (2024).","journal-title":"Ann. Oncol."},{"key":"1104_CR170","doi-asserted-by":"publisher","first-page":"CT101","DOI":"10.1158\/1538-7445.AM2025-CT101","volume":"85","author":"L Dyrskj\u00f8t","year":"2025","unstructured":"Dyrskj\u00f8t, L. et al. Abstract CT101: ctDNA-guided immunotherapy following cystectomy in patients with urothelial carcinoma: preliminary results from the TOMBOLA trial. Cancer Res. 85, CT101 (2025).","journal-title":"Cancer Res."},{"key":"1104_CR171","doi-asserted-by":"publisher","unstructured":"Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2511885 (2025).","DOI":"10.1056\/NEJMoa2511885"},{"key":"1104_CR172","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR173","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR174","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483\u20131492 (2017).","journal-title":"Lancet Oncol."},{"key":"1104_CR175","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados, B. et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur. Urol. 82, 212\u2013222 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR176","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"1104_CR177","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353\u20133360 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR178","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839\u20131844 (2020).","journal-title":"Nat. Med."},{"key":"1104_CR179","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.eururo.2024.06.018","volume":"86","author":"ER Plimack","year":"2024","unstructured":"Plimack, E. R. et al. Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial. Eur. Urol. 86, 297\u2013300 (2024).","journal-title":"Eur. Urol."},{"key":"1104_CR180","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"1104_CR181","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl, G. et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur. Urol. 81, 523\u2013532 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 4858 (2020).","journal-title":"Nat. Commun."},{"key":"1104_CR183","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","volume":"36","author":"CS Groeneveld","year":"2025","unstructured":"Groeneveld, C. S. et al. Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial. Ann. Oncol. 36, 89\u201398 (2025).","journal-title":"Ann. Oncol."},{"key":"1104_CR184","doi-asserted-by":"publisher","first-page":"TPS4621","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4621","volume":"42","author":"SJ Crabb","year":"2024","unstructured":"Crabb, S. J. et al. Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. J. Clin. Oncol. 42, TPS4621 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR185","doi-asserted-by":"publisher","first-page":"104433","DOI":"10.1016\/j.critrevonc.2024.104433","volume":"201","author":"D Horgan","year":"2024","unstructured":"Horgan, D. et al. From theory to practice: implementing next-generation sequencing and public health genomics in healthcare systems. Crit. Rev. Oncol.\/Hematol. 201, 104433 (2024).","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"1104_CR186","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00654","volume":"8","author":"G Vandekerkhove","year":"2024","unstructured":"Vandekerkhove, G. et al. Toward informed selection and interpretation of clinical genomic tests in prostate cancer. JCO Precis. Oncol. 8, e2300654 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1104_CR187","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.4111\/icu.2016.57.S1.S4","volume":"57","author":"M Miyake","year":"2016","unstructured":"Miyake, M., Fujimoto, K. & Hirao, Y. Active surveillance for nonmuscle invasive bladder cancer. Investig. Clin. Urol. 57, S4\u2013S13 (2016).","journal-title":"Investig. Clin. Urol."},{"key":"1104_CR188","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.juro.2017.08.091","volume":"199","author":"R Hurle","year":"2018","unstructured":"Hurle, R. et al. Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project. J. Urol. 199, 401\u2013406 (2018).","journal-title":"J. Urol."},{"key":"1104_CR189","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1200\/JCO.2024.42.16_suppl.4600","volume":"42","author":"J Linscott","year":"2024","unstructured":"Linscott, J. et al. Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC). J. Clin. Oncol. 42, 4600 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR190","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s11912-024-01555-0","volume":"26","author":"JA Linscott","year":"2024","unstructured":"Linscott, J. A. et al. From detection to cure \u2014 emerging roles for urinary tumor DNA (utDNA) in bladder cancer. Curr. Oncol. Rep. 26, 945\u2013958 (2024).","journal-title":"Curr. Oncol. Rep."},{"key":"1104_CR191","doi-asserted-by":"publisher","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","volume":"15","author":"FC de Jong","year":"2023","unstructured":"de Jong, F. C. et al. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette\u2013Gu\u00e9rin. Sci. Transl. Med. 15, eabn4118 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1104_CR192","doi-asserted-by":"publisher","unstructured":"Ferro, M. et al. Artificial intelligence in the advanced diagnosis of bladder cancer \u2014 comprehensive literature review and future advancement. Diagnostics (Basel) https:\/\/doi.org\/10.3390\/diagnostics13132308 (2023).","DOI":"10.3390\/diagnostics13132308"},{"key":"1104_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.006","author":"VT Packiam","year":"2025","unstructured":"Packiam, V. T. et al. Presence of an artificial intelligence-powered predictive biomarker is associated with a poor response to intravesical Bacillus Calmette\u2013Guerin but not to intravesical sequential gemcitabine\/docetaxel in patients with high-grade non-muscle-invasive bladder cancer. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.04.006 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR194","doi-asserted-by":"publisher","unstructured":"Khoraminia, F. et al. Artificial intelligence in digital pathology for bladder cancer: hype or hope? A systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15184518 (2023).","DOI":"10.3390\/cancers15184518"},{"key":"1104_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.11.026","author":"M-P St-Laurent","year":"2024","unstructured":"St-Laurent, M.-P. et al. Increasing life expectancy in patients with genitourinary malignancies: impact of treatment burden on disease management and quality of life. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.026 (2024).","journal-title":"Eur. Urol."},{"key":"1104_CR196","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.juro.2017.10.049","volume":"199","author":"MM Casilla-Lennon","year":"2018","unstructured":"Casilla-Lennon, M. M. et al. Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life. J. Urol. 199, 1166\u20131173 (2018).","journal-title":"J. Urol."},{"key":"1104_CR197","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.euf.2023.12.002","volume":"10","author":"R Contieri","year":"2024","unstructured":"Contieri, R. et al. The financial burden of guideline-recommended cancer medications for metastatic urothelial carcinoma. Eur. Urol. Focus 10, 662\u2013665 (2024).","journal-title":"Eur. Urol. Focus"},{"key":"1104_CR198","doi-asserted-by":"publisher","first-page":"1464092","DOI":"10.3389\/fimmu.2024.1464092","volume":"15","author":"A Li","year":"2024","unstructured":"Li, A. et al. Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States. Front. Immunol. 15, 1464092 (2024).","journal-title":"Front. Immunol."},{"key":"1104_CR199","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","volume":"87","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti, P. et al. The financial burden of localized and metastatic bladder cancer. Eur. Urol. 87, 536\u2013550 (2025).","journal-title":"Eur. Urol."},{"key":"1104_CR200","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000019824","volume":"35","author":"J Irani","year":"1999","unstructured":"Irani, J. et al. BTA stat and BTA TRAK: a comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur. Urol. 35, 89\u201392 (1999).","journal-title":"Eur. Urol."},{"key":"1104_CR201","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/S0022-5347(05)68934-3","volume":"161","author":"C Mian","year":"1999","unstructured":"Mian, C. et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 161, 1486\u20131489 (1999).","journal-title":"J. Urol."},{"key":"1104_CR202","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/modpathol.3800262","volume":"18","author":"B T\u00eatu","year":"2005","unstructured":"T\u00eatu, B., Tiguert, R., Harel, F. & Fradet, Y. ImmunoCyt\/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod. Pathol. 18, 83\u201389 (2005).","journal-title":"Mod. Pathol."},{"key":"1104_CR203","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/j.1464-410X.2008.07473.x","volume":"101","author":"Y Lotan","year":"2008","unstructured":"Lotan, Y. & Shariat, S. F. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int. 101, 1362\u20131367 (2008).","journal-title":"BJU Int."},{"key":"1104_CR204","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.euo.2019.06.006","volume":"3","author":"T Dudderidge","year":"2020","unstructured":"Dudderidge, T. et al. A novel, non-invasive test enabling bladder cancer detection in urine sediment of patients presenting with haematuria \u2014 a prospective multicentre performance evaluation of ADXBLADDER. Eur. Urol. Oncol. 3, 42\u201346 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR205","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/JU.0000000000001084","volume":"204","author":"M Roupret","year":"2020","unstructured":"Roupret, M. et al. Diagnostic accuracy of MCM5 for the detection of recurrence in nonmuscle invasive bladder cancer followup: a blinded, prospective cohort, multicenter European study. J. Urol. 204, 685\u2013690 (2020).","journal-title":"J. Urol."},{"key":"1104_CR206","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02796-4","volume":"19","author":"Y Hirasawa","year":"2021","unstructured":"Hirasawa, Y. et al. Diagnostic performance of Oncuria\u2122, a urinalysis test for bladder cancer. J. Transl. Med. 19, 141 (2021).","journal-title":"J. Transl. Med."},{"key":"1104_CR207","doi-asserted-by":"publisher","unstructured":"Zhang, Z. et al. GG02-30 Oncuria-monitor, a non-invasive test for the detection of recurrent bladder cancer: cross sectional performance evaluation from a multicenter study. J. Urol. https:\/\/doi.org\/10.1097\/01.JU.0001109860.96928.64.30 (2025).","DOI":"10.1097\/01.JU.0001109860.96928.64.30"},{"key":"1104_CR208","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cncy.21327","volume":"121","author":"H Dimashkieh","year":"2013","unstructured":"Dimashkieh, H. et al. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 121, 591\u2013597 (2013).","journal-title":"Cancer Cytopathol."},{"key":"1104_CR209","doi-asserted-by":"publisher","unstructured":"Harvey, J. C. et al. Analytical validation of Cxbladder(\u00ae) detect, triage, and monitor: assays for detection and management of urothelial carcinoma. Diagnostics (Basel) https:\/\/doi.org\/10.3390\/diagnostics14182061 (2024).","DOI":"10.3390\/diagnostics14182061"},{"key":"1104_CR210","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.juro.2016.12.010","volume":"197","author":"L Kavalieris","year":"2017","unstructured":"Kavalieris, L. et al. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J. Urol. 197, 1419\u20131426 (2017).","journal-title":"J. Urol."},{"key":"1104_CR211","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.urolonc.2024.01.184","volume":"42","author":"N Fleshner","year":"2024","unstructured":"Fleshner, N. et al. Consistent performance of bladder epicheck for NMIBC surveillance in the USA and European pivotal studies and in real world studies. Urol. Oncol. Semin. Original Investig. 42, S63 (2024).","journal-title":"Urol. Oncol. Semin. Original Investig."},{"key":"1104_CR212","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3389\/fgene.2019.01237","volume":"10","author":"R Batista","year":"2019","unstructured":"Batista, R. et al. Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study. Front. Genet. 10, 1237 (2019).","journal-title":"Front. Genet."},{"key":"1104_CR213","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01029-1","volume":"13","author":"P Piatti","year":"2021","unstructured":"Piatti, P. et al. Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. Clin. Epigenet. 13, 84 (2021).","journal-title":"Clin. Epigenet."},{"key":"1104_CR214","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.eururo.2018.11.055","volume":"75","author":"FJPV Valenberg","year":"2019","unstructured":"Valenberg, F. J. P. V. et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur. Urol. 75, 853\u2013860 (2019).","journal-title":"Eur. Urol."},{"key":"1104_CR215","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.euo.2020.09.001","volume":"4","author":"F Valenberg","year":"2021","unstructured":"Valenberg, F. et al. Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur. Urol. Oncol. 4, 93\u2013101 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR216","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.juro.2016.09.118","volume":"197","author":"KE van Kessel","year":"2017","unstructured":"van Kessel, K. E. et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J. Urol. 197, 590\u2013595 (2017).","journal-title":"J. Urol."},{"key":"1104_CR217","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.1158\/1078-0432.CCR-20-0401","volume":"26","author":"S Zeng","year":"2020","unstructured":"Zeng, S. et al. Noninvasive detection of urothelial carcinoma by cost-effective low-coverage whole-genome sequencing from urine-exfoliated cell DNA. Clin. Cancer Res. 26, 5646\u20135654 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR218","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32143","volume":"7","author":"SU Springer","year":"2018","unstructured":"Springer, S. U. et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife 7, e32143 (2018).","journal-title":"eLife"},{"key":"1104_CR219","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.eururo.2024.10.014","volume":"87","author":"J Nikkola","year":"2025","unstructured":"Nikkola, J. et al. Sensitive detection of urothelial cancer via high-volume urine DNA analysis. Eur. Urol. 87, 86\u201388 (2025).","journal-title":"Eur. Urol."},{"key":"1104_CR220","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0570","author":"K Salari","year":"2023","unstructured":"Salari, K. et al. Development and multicenter case\u2013control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0570 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR221","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","volume":"6","author":"DG Ward","year":"2023","unstructured":"Ward, D. G. et al. Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA. Eur. Urol. Oncol. 6, 67\u201375 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR222","unstructured":"US Food and Drug Administration. 761336Orig1s000 Multi-discipline review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761336Orig1s000MultidisciplineR.pdf (2024)."},{"key":"1104_CR223","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.03","volume":"213","author":"JM Jacob","year":"2025","unstructured":"Jacob, J. M. et al. TAR-200 monotherapy in patients with Bacillus Calmette\u2013Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from SunRISe-1. J. Urol. 213, e2 (2025).","journal-title":"J. Urol."},{"key":"1104_CR224","doi-asserted-by":"publisher","first-page":"S1272","DOI":"10.1016\/j.annonc.2024.08.2329","volume":"35","author":"MS van der Heijden","year":"2024","unstructured":"van der Heijden, M. S. et al. LBA85 TAR-200 +\/- cetrelimab (CET) and CET alone in patients (pts) with Bacillus Calmette\u2013Gu\u00e9rin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): updated results from SunRISe-1 (SR-1). Ann. Oncol. 35, S1272\u2013S1273 (2024).","journal-title":"Ann. Oncol."},{"key":"1104_CR225","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001015816.87470.c9.02","volume":"211","author":"MD Tyson","year":"2024","unstructured":"Tyson, M. D. et al. P2-02\u2003pivotal results from BOND-003: a phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. J. Urol. 211, e1 (2024).","journal-title":"J. Urol."},{"key":"1104_CR226","doi-asserted-by":"publisher","first-page":"TPS598","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS598","volume":"40","author":"EM Uchio","year":"2022","unstructured":"Uchio, E. M. et al. A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette\u2013Guerin (BCG). J. Clin. Oncol. 40, TPS598 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR227","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.2023.41.6_suppl.528","volume":"41","author":"GS Kulkarni","year":"2023","unstructured":"Kulkarni, G. S. et al. A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis). J. Clin. Oncol. 41, 528\u2013528 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR228","doi-asserted-by":"publisher","first-page":"TPS4626","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4626","volume":"42","author":"R Bryce","year":"2024","unstructured":"Bryce, R., Tosone, C., Sullivan, J. C., Linback, T. & Steinberg, G. D. A phase 1\/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. J. Clin. Oncol. 42, TPS4626 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR229","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","volume":"16","author":"CN Sternberg","year":"2015","unstructured":"Sternberg, C. N. et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 16, 76\u201386 (2015).","journal-title":"Lancet Oncol."},{"key":"1104_CR230","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/bju.16556","volume":"135","author":"R Ben-David","year":"2025","unstructured":"Ben-David, R. et al. Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. BJU Int. 135, 473\u2013480 (2025).","journal-title":"BJU Int."}],"updated-by":[{"DOI":"10.1038\/s41571-026-01121-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01104-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01104-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:02:24Z","timestamp":1771938144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01104-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":230,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01104-z","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"3 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-026-01121-6","URL":"https:\/\/doi.org\/10.1038\/s41571-026-01121-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}